Nektar Therapeutics traded at $2.46 this Thursday January 26th, increasing $0.13 or 5.58 percent since the previous trading session. Looking back, over the last four weeks, Nektar Therapeutics gained 21.18 percent. Over the last 12 months, its price fell by 76.25 percent. Looking ahead, we forecast Nektar Therapeutics to be priced at 2.24 by the end of this quarter and at 2.03 in one year, according to Trading Economics global macro models projections and analysts expectations.


Ok
Trading Economics members can view, download and compare data from nearly 200 countries, including more than 20 million economic indicators, exchange rates, government bond yields, stock indexes and commodity prices.

The Trading Economics Application Programming Interface (API) provides direct access to our data. It allows API clients to download millions of rows of historical data, to query our real-time economic calendar, subscribe to updates and receive quotes for currencies, commodities, stocks and bonds.

Please Paste this Code in your Website
width
height
Peers Price Day Year
Takeda 4,137.00 -39.00 -0.93% 24.35%
Eisai 8,147.00 -134.00 -1.62% 40.42%
Agios Pharmaceuticals 30.72 -0.06 -0.19% 5.10%
ALKERMES 28.50 0.16 0.56% 16.04%
Amgen 254.88 -1.66 -0.65% 13.79%
AstraZeneca 65.99 -0.64 -0.96% 10.87%
Baxter International 46.18 0.04 0.08% -45.44%
BioCryst Pharmaceuticals 10.78 -0.01 -0.09% -23.65%
Biogen 291.92 -0.42 -0.14% 33.33%
Bluebird Bio 6.23 -0.10 -1.58% -14.66%
Bristol-Myers Squibb 72.99 -0.18 -0.25% 12.45%
Cara Therapeutics 12.27 0.17 1.41% 11.65%
Dr.Reddys Laboratories 4,352.45 151.50 3.61% 2.26%
Esperion Therapeutics 6.65 -0.04 -0.60% 82.19%
Exelixis 17.71 0.38 2.19% 1.66%
Gilead Sciences 83.62 -0.45 -0.54% 21.43%
GlaxoSmithKline 1,405.20 1.60 0.11% -16.41%
Halozyme Therapeutics 53.28 0.79 1.51% 66.66%
Immunogen 4.71 -0.08 -1.67% -7.47%
Incyte Corp 86.01 1.04 1.22% 20.14%
Ionis Pharmaceuticals 39.38 -0.37 -0.93% 30.66%
Ironwood Pharmaceuticals 11.31 0.01 0.09% 6.30%
Karyopharm Therapeutics 3.13 -0.09 -2.80% -60.00%
Eli Lilly 348.01 -1.72 -0.49% 41.99%
MacroGenics 5.92 -0.30 -4.82% -47.66%
Merck & Co 106.87 -1.72 -1.58% 32.10%
Mirati Therapeutics 51.06 1.84 3.74% -52.65%
Neurocrine Biosciences 108.38 -0.42 -0.39% 49.59%
Nektar Therapeutics 2.46 0.13 5.58% -76.25%
Novartis 82.68 -2.62 -3.07% 3.78%
Pfizer 44.19 -0.88 -1.95% -17.20%
Roche Holding 289.00 -4.60 -1.57% -18.50%
Seattle Genetics 139.69 1.68 1.22% 13.65%
Sarepta Therapeutics 124.47 1.31 1.06% 86.11%
Teva Pharmaceutical Industries Ltd 3,459.00 54.00 1.59% 27.17%
Xencor 31.78 -0.81 -2.49% -0.44%

Indexes Price Day Year
USND 11512 199.06 1.76% -13.78%
US2000 1903 12.75 0.67% -1.46%
US400 2610 22.34 0.86% 3.17%

Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical company. The Company discovers and develops medicines in areas of unmet medical need. Its research and development pipeline of new investigational drugs includes treatments for cancer and autoimmune disease. It has research and development (R&D) pipeline of medicines in oncology, immunology, and virology as well as a portfolio of approved partnered medicines. It leverages its chemistry platform to discover and design new drug candidates. These drug candidates utilize its polymer conjugate technology platforms, which are designed to enable the development of new molecular entities. Its R&D pipeline includes Bempegaldesleukin (NKTR-214), NKTR-358, NKTR-262 and NKTR-255. It develops medicines designed to modulate the activity of key immune cells, such as cytotoxic T cells and Natural Killer (NK) cells, to increase their numbers and improve their function to recognize and attack cancer cells directly or indirectly.